We work closely with entrepreneurs and investors at the forefront of the global healthcare revolution. Our in-depth sector knowledge, combined with our technical capability, enables us to help corporates and investors capitalise on the enormous opportunities across the sector as they seek to consolidate and grow their market positions.
The ageing population, technological change, and increased demand for healthcare products and services, all create great opportunities in the health and social care, medical devices, life sciences, bioscience and pharmaceutical markets. Our job is to help our clients maximise those opportunities.
Adviser to MBO & Co on the acquisition of a minority stake in CMN Group
View moreAdvisor to PSD on its refinancing and the financing of Optipharma
View moreAdviser to Capidea on the sale of BROEN-LAB to LI Enterprises Group
View moreAdviser to Lexon on refinancing to aid its growth strategy
View moreAdviser to Medequip on its sale to Medux
View moreAdviser to Dayes B.V. on its acquisition of Healthpoint
View moreAdviser to Fisiopharma on its sale to Laboratorios Rubió
View moreAdviser to Hôpital Privé La Casamance on its sale to Almaviva Santé
View moreAdviser to Maven Capital Partners on the sale of Westfield Medical to Sterimed Group
View moreAdviser to WEP on its investment from The Jordan Company
View moreAdviser to Evergreen on raising strategic finance
Adviser to Gradiente on raising finance to support the acquisition of a majority stake in the share capital of Giuriati Group S.r.l.
View moreLuc Bertholat, Partner, Naxicap PartnersClearwater has been very professional in leading the process involving candidates from all over the world.
The team were quickly able to identify the right partner for us and used their excellent relationship with the buyer to help negotiate a transaction that met our objectives.Dan Smart, CEO, Proclinical
With in-depth knowledge and technical capability, our healthcare team has a great track record of delivering tailored solutions.
See our teamOver 80
deals advised upon
in the last 5 years
€14.5bn
in deal value
over the last 5 years
Over 40%
deals involving PE
in the last 5 years
Following the publication of the Q1 2022 Clearwater International Multiples Heatmap, Mergermarket interviewed Clearwater’s executive team to discuss trends driving deal activity in healthcare.
Read more
PE deals accounted for one-third of all Q1 M&A transactions in 2022, one of the highest proportions on record. Our latest Multiples Heatmap report explores the major themes driving EV/EBITDA multiples in European PE deals with the goal to assist PE investors with their strategic decisions.
Read more
Dealmaking in Europe’s Southern region – comprising Spain, Italy and Portugal – slowed somewhat in Q1 2022. Despite this, there were some notable hotspots, including in the healthcare, food and beverage, and TMT sectors, as Clearwater International’s Bruno Pinho, partner in Portugal, and Josemaría Torrens, director in Spain, discuss.
Read more
